Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Oklahoma City, OK
NPI: 1154434405Primary Practice Location
O U MEDICAL CENTER
1200 N Childrens Ave, Oklahoma City, OK
Primary Employer
OU Health Partners
ouhealth.com
HQ Phone
Get M.D. Adam's Phone Numberphone_androidMobile
Get M.D. Adam's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNC State Medical License
OK State Medical License
OK State Medical License
2014 - 2025
NC State Medical License
2006 - 2015
NY State Medical License
1982 - 2008
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
New York Presbyterian Hospital (Cornell Campus)
Fellowship • Hematology and Medical Oncology
1982 - 1984
Zucker School of Medicine at Hofstra/Northwell
Residency • Internal Medicine
1979 - 1982
Swarthmore College
BA
—
Sidney Kimmel Medical College
jefferson.edu
Medical School
Until 1979
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 99 | 164 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 63 | 327 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 32 | 37 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 31 | 37 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 21 | 21 |
Authors: Sigounas, George, Hairr, Jonathan W, Cooke, Charles D, Owen, Jennifer R, Asch, Adam S, Weidner, Douglas A, Wiley, John E
Journal: Free Radic Biol Med
Publication Date: 2010-03-25
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Authors: Natalie Grover, Oludamilola Olajide, Matthew Foster
Publication Date: 2016-01-26
Lead Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Intervention / Treatment: BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + venetoclax, BIOLOGICAL: JCAR017 (lisocabtagene maraleucel), BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + ibrutinib
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Cancer Research UK, European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Irish Group CTI
Intervention / Treatment: DRUG: carboplatin, DRUG: cisplatin, DRUG: paclitaxel, DRUG: ifosfamide, DRUG: G-CSF, DRUG: etoposide phosphate, DRUG: pegylated G-CSF, PROCEDURE: stem cell reinfusion
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Docetaxel, DRUG: Ramucirumab
